President and CEO, Curtana Pharmaceuticals
Gregory Stein, MD, MBA currently serves as the President and CEO of Curtana Pharmaceuticals, a privately held, preclinical-stage biopharmaceutical company headquartered in Austin, Texas that focuses on the development of novel first-in-class, small molecule therapeutics targeting cancer stem cells for the treatment of glioblastoma and other brain cancers. Prior to founding Curtana, Dr. Stein was a co-founder of Sova Pharmaceuticals, where he had the role of Vice President, Operations. Sova is focused on the development of novel therapeutic drugs for the treatment of inflammatory and neuropathic pain. Prior to Sova, he was the Senior Director of Product Marketing at Genoptix, a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists; the company was acquired by Novartis. During his professional career of over 25 years, Dr. Stein has been a clinician, a hospital administrator, and a life sciences executive with experience in the areas of diagnostics, medical devices, pharmaceuticals and biotechnology.
Dr. Stein is formerly board certified in Emergency Medicine. He completed his residency at the University of Illinois Affiliated Hospitals in Chicago and is a graduate of the 3-year accelerated Independent Study Program at the Ohio State University School of Medicine. Dr. Stein received a B.A in Psychology from UC San Diego and an MBA from The Rady School of Management at UC San Diego.